Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sunitinib or Valproic Acid in High-Risk Uveal Melanoma
NCT02068586Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2014
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib and valproic acid in Uveal melanoma (UM) (4 cohorts), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Overall Survival at 2 years and Relapse-Free Survival at 2 years. Started Nov 2014; status: active, not recruiting.
02
Drugs
sunitinibvalproic acid
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02068586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068586.